2026-04-14T05:26:07Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/138662025-10-25T05:38:38Zcom_2072_378072com_2072_378040col_2072_378100

00925njm 22002777a 4500 dc Boscolo Bielo , Luca author Aftimos, Philippe author Beltran, Himisha author Benary, Manuela author Westphalen, Benedikt author Chakravarty, Debyani author Dienstmann, Rodrigo author Mateo, Joaquin author 2025-10-16T06:17:59Z 2025-10-16T06:17:59Z 2025-06 Molecular tumour boards; Precision medicine; Precision oncology Juntas de tumores moleculares; Medicina de precisión; Oncología de precisión Juntes de tumors moleculars; Medicina de precisió; Oncologia de precisió Background With an increased uptake of genomic profiling in clinical practice and the evolving complexity of diagnostic modalities, vast amounts of complex data need to be properly interpreted and integrated into an individualised care plan. To address these challenges, molecular tumour boards (MTBs) have been widely established. As of today, no international recommendations regulating the composition and workflows of MTBs have been defined. Methods ESMO’s Precision Oncology Working Group (POWG) established an international expert panel in precision oncology and defined core areas of interest. After several consultations and through an expert consensus process, the group reached a consensus level for each recommendation. Results The group defined five components in the MTB process that are critical to its function and clinical use: (i) the primary task of MTBs consists in providing genomic-informed clinical recommendations, particularly for cases exhibiting complex genomic alterations; (ii) to achieve this, MTBs should encompass interdisciplinary expertise, with key roles for oncologists with genomic expertise, pathologists with molecular training and clinical geneticists; (iii) MTBs’ recommendations should be documented in a structured report that includes genomic-informed treatment strategies, management plans for potential tumour-detected germline alterations and guidance for additional genomic testing; (iv) structured follow-up processes should be implemented for monitoring the clinical effectiveness of MTBs recommendations and (v) finally, the panel proposed quality indicators for operating MTBs, including turnaround times for cases discussion and the proportion of cases for which actionable recommendations and clinical trial enrolments were successfully implemented. Conclusions These ESMO’s POWG recommendations can serve as a guidance and help to define quality standards for MTBs to allow for harmonisation and to further expedite the integration of precision oncology into clinical practice. This project was funded by the European Society for Medical Oncology (no grant number). http://hdl.handle.net/11351/13866 Càncer - Tractament Genòmica Medicina personalitzada Assistència sanitària - Control de qualitat DISEASES::Neoplasms Other subheadings::Other subheadings::/therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine DISCIPLINES AND OCCUPATIONS::Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics HEALTH CARE::Health Services Administration::Quality of Health Care::Quality Indicators, Health Care ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::/terapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión DISCIPLINAS Y OCUPACIONES::disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica ATENCIÓN DE SALUD::administración de los servicios de salud::calidad de la atención sanitaria::indicadores de calidad en la asistencia sanitaria ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice